GlaxoSmithKline (GSK) and Miltenyi Biotec have partnered to unite the cell and gene therapy-based treatments from GSK, with the cell processing and related cell therapy technologies from Miltenyi Biotec.
The goal is to make the most efficient, personalized therapies that can be produced and delivered effectively. These therapies will be developed with cutting-edge processing technology as well as automation.
“Cell-based gene therapies are living treatments, unique to individual patients and complex to manufacture,” Patrick Vallance, president of pharmaceutical research and development at GSK, said. “We see tremendous potential for the cell and gene therapy platform we are building within GSK; however, the complexity of current manufacturing processes limits their use to local treatment of small patient populations. Working with Miltenyi Biotec, our vision is to transform current technology, so that we can expand the possibilities for cell and gene therapy treatment to wider patient populations with broader geographical reach.”
The collaboration also covers a CAR-T cell-based oncology therapy program.
“For more than 20 years, we have been developing and providing cell therapy solutions to patients worldwide,” Miltenyi Biotec President and CEO Stefan Miltenyi said. “Working together with the global experts at GSK, we will accelerate innovation to broaden patient access to future personalized cell and gene therapy.”